Windlas Biotech IPO – Review, Bid, Size, Allotment, Subscription, GMP & RHP
Let’s have a detailed review of the company and analytics of the Windlas Biotech IPO release date, IPO offer price, subscription, Windlas Biotech Limited IPO allotment, grey market price, and other details like the company’s background, its financial positions, its promoters, and other related things.
|Face Value||Rs 5|
|Cash Price||Rs [●]|
|Listing At||BSE, NSE|
|Min. Order Quantity||NA|
|Offer for Sale||Rs Million|
|Fresh Issue||Rs1,650 MILLION|
|IPO Size||Rs Million|
Windlas Biotech IPO is listed at a [●] premium. Check out the live share price by clicking on the below link.
|Live Performance – Windlas Biotech Share Price|
Windlas Biotech IPO – Summary
They are amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue (Source: CRISIL Report).
With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances, and low solubility, They provide a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (“GMP”) with a focus on improved safety, efficacy and cost.
The Promoter of this company is Mr. Ashok Kumar Windlass. The lead manager to the issue is SBI Capital Markets Limited, DAM Capital Advisors Limited, and IIFL Securities Limited, The Registrar to this issue is Link Intime India Private Limited.
Windlas Biotech IPO Date
The opening and the closing date of the IPO of Windlas Biotech Limited are not available yet.
Windlas Biotech IPO Subscription
|Day / Date||QIB||NII||RII||Total Subscription|
|1st Day –|
|2nd Day –|
|3rd Day –|
|Shares Offered or Net Issue|
The shares subscribed by the public will be updated here.
Check Windlas Biotech IPO LIVE Subscription
- Windlas Biotech IPO LIVE Bid details on BSE
- Windlas Biotech IPO LIVE Bid details on NSE
For the Latest Bid details click on the above links.
Windlas Biotech IPO Allotment Status
Here, you can find the Allotment Status of this IPO.
Allotment of Equity Shares pursuant to the Fresh Issue and transfer of the Offered Shares of the Promoter Selling Shareholders pursuant to the Offer for Sale to the successful Bidders. However, the Allotment Status is not yet disclosed.
Windlas Biotech Limited IPO Listing Date
Find the dates below on basis of allotment, refund, listing, and more:
|Basis of Allotment Finalization||–|
|The credit of Shares to Demat Account||–|
|Share Listing Date||–|
Windlas Biotech IPO Cash Price
The face value of each share is Rs.5, but the Cash price of the IPO is Rs.[●]
Windlas Biotech IPO Equity Size
This Initial Public Issue of X Equity Shares of Rs.5 each for cash at a price of Rs.[●] per equity share aggregating to Rs.1,650 million
Windlas Biotech IPO Share Offering
Fresh Issue: The Issue (excluding the Market Maker Reservation Portion) of [●] Equity Shares of Rs.10/ each.
Issue Size: X Equity Shares of Rs.10 each, aggregating to Rs.[●] Million
Windlas Biotech IPO – Live Performance
The listing date of this IPO is [●]. You can check the live performance of the IPO here, only after it is listed on exchanges.
|Live IPO Performance – Windlas Biotech Share Price|
Windlas Biotech IPO Grey Market Premium
The Windlas Biotech Limited IPO Grey Market Premium price is Rs X, the Kostak rate is Rs X and the Subject to Sauda is X.
Windlas Biotech IPO – Company Overview
The prevalence of chronic diseases in India has been increasing in the last few years, specifically in certain key therapeutic categories, such as, anti-diabetic, cardiovascular, neuropsychiatry, and respiratory therapies, that are treated with ‘multi-drug therapy’ by physicians, i.e. the specific use of two or more drugs for single or multiple chronic conditions in an individual.
Moreover, multi-drug therapy has gained importance over the past few years in the healthcare sector and is expected to aid the growth of pharmaceutical consumption. (Source: CRISIL Report). They have significant experience in developing and manufacturing generic fixed-dose combinations.
Our focus has currently been on launching new complex generic products in the chronic therapeutic category linked to lifestyle-related disorders.
Windlas Biotech IPO – Financial Statements
A quick look into the past financial performance of the company to understand its performance of the business and evaluate the growth prospectus:
|Amount (in INR & Million)|
|Profit After Tax||96.74||162.13||638.22||111.98|
Earnings per Equity Share (in Million)
Further, their PAT for the period ended on December 31, 2020, March 31, 2020, March 31, 2019, and March 31, 2018, were Rs. 96.74 Million, Rs. 162.13 Million, Rs. 638.22 Million, and Rs. 111.98 Million respectively.
Windlas Biotech IPO – Promoters
The Promoter of this company is:
- Ashok Kumar Windlass
List of Related Parties (Key Managerial Personnel)
- Mr. Vivek Dhariwal, Chairman and Non-Executive Independent Director
- Mr. Ashok Kumar Windlass, Wholetime Director
- Mr. Hitesh Windlass, Managing Director
- Mr. Manoj Kumar Windlass, Joint Managing Director.
- Mr. Pawan Kumar Sharma, Executive Director.
Windlas Biotech IPO – Promoters Holding
- Pre Issue Share Holding – 24.17%
- Post Issue Share Holding – NA %
Windlas Biotech IPO Offer Details or Issue Details
|Particulars||No. Of Equity Shares|
|Equity Shares Offered||Up to X Equity Shares aggregating up to Rs.[●] Million|
|Fresh Issue||Up to [●] Equity Shares aggregating up to Rs.1,650 million.|
|Net Issue to the Public||Up to [●] Equity Shares aggregating up to Rs.[●]|
|Retail Investors Portion||Not less than [●] Equity Shares|
|Other than Retail Individual Investors||Not more than [●] Equity Shares|
|Equity Shares outstanding prior to the Issue||18,207,419 Equity Shares|
|Equity Shares outstanding after the Issue||X Equity Shares|
Windlas Biotech IPO Issue Object
Their Company proposes to utilize the Net Proceeds towards funding the following objects:
- Purchase of equipment required for (i) capacity expansion of our existing facility at Dehradun Plant – IV; and (ii) addition of injectables dosage capability at our existing facility at Dehradun Plant-II;
- General Corporate Purpose
- To meet issue expenses
- Repayment/prepayment of certain of our borrowings
Windlas Biotech IPO – Business Strategy
- Capitalize on expansion opportunities by leveraging our leadership position in the CDMO industry
- Continue to grow our CDMO customer base
- Expand our product portfolio and delivery systems by enhancing R&D and manufacturing capabilities
- Focus on the Domestic Trade Generics and OTC Brands SBV and high growth export markets by capitalizing on industry
Windlas Biotech IPO – Basis of Offer Price
The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.
Qualitative factors are:
- Leading CDMO in India with a focus on the chronic therapeutic category
- Innovative portfolio of complex generic products supported by robust R&D capabilities
- Efficient and quality compliant manufacturing facilities with significant entry barriers
- Strong and long-term relationships with leading Indian pharmaceuticals companies
The relevant quantitative factors are:
|Basic EPS||Diluted EPS||RONW (%)||NAV (Rs.)|
Windlas Biotech IPO: Competitive Peers
|Face Value (Rs.)||P/E||EPS (Rs.)||Return on Net Worth (%)||Total Income (Rs. in Million)|
|Windlas Biotech Limited||5||[●]||8.90||8.5||96.74|
Windlas Biotech IPO Lead Managers
SBI Capital Markets Limited,
DAM Capital Advisors Limited,
IIFL Securities Limited
Windlas Biotech IPO Registrar to offer
|Registrar to the Offer|
|Link Intime India Private Limited|
C-101, 1st Floor 247 Park, Lal Bhadur Shastri Marg
Vikhroli (West), Mumbai 400 083, Maharashtra, India
Tel: +91 22 4918 6200
Investor Grievance ID:
Contact Person: Shanti Gopalkrishnan
SEBI Registration Number: INR000004058
Windlas Biotech IPO – Other Details
- Statutory Auditor – S. S. Kothari Mehta & Company
- Legal Counsel to the Company – Cyril Amarchand Mangaldas
- Bankers to the Company – State Bank of India, HDFC Bank Ltd. IndusInd Bank Limited.
Windlas Biotech IPO Review by Stock Brokers
|Top Stock Brokers Review||Company Reputation||Competitive Edge||Financial Statement||Popularity Index||Promoters Reputation|
Subscribe to Windlas Biotech IPO
Windlas Biotech Limited IPO News
News 1 – IPO DRHP Download
News 2 – IPO RHP Prospectus Download
Windlas Biotech IPO Review FAQs
Ques – What is the Issue Size of Windlas Biotech IPO?
Answer – The Company is making an initial public offer of NA equity shares. We vividly portray the aspects of the issue in this article. You can check the stats on the fresh issue, Offer for sale, and net issue.
Ques – What is the Cash Price of Windlas Biotech IPO?
Answer – The Cash price for this particular IPO Is NA. As far as the face value of the share is of concern, it is Rs.5 per share.
Ques – What is the Windlas Biotech IPO Open Date?
Answer – The opening and closing dates for this IPO have been updated. The IPO is set to open on NA, while the closing date is set at NA.
Ques – What is the Windlas IPO Allotment Date?
Answer – We also have the news regarding the respective allotment dates of this IPO. The basis of Allotment finalization is on X, refund initiation is on NA, credit of shares is on NA, and share listing date is on NA.
Ques – What is the Windlas Biotech IPO Listing Date?
Answer – Shares of this company shall be listed in the exchanges NA. The date, when the listing would be done, is stagnant on X.
Ques – Who is the Registrar of Windlas IPO?
Answer – One of the reputed registrars is managing the issue of this IPO, i.e. Link Intime India Private Limited. Their website will help you regarding the further information you are on the lookout for.
Ques – Who is the Promoter of Windlas IPO?
Answer – Here are the promoters of this IPO –Ashok Kumar Windlass You can refer to the RHP for further information on the promoter. You will find the link to RHP in the article.
Ques – What is GMP of Windlas Biotech IPO?
Answer – We have obtained the GMP of this IPO and it is NA. Further insights of Kostak rate and subject to sauda or SS are as well included in this report.
Ques – Is Windlas IPO good for Investment?
Answer – We have further provided the financial status of the company in this article, from the past few years. You can refer to the same, and also check the line of operations they are into and then decide to invest in the IPO.
Ques – What is the PAT of Windlas Biotech Ltd?
Answer – We have the information of company financials, and according to that, we have the figures from the last few years to provide. Their PAT for the period ended on December 31, 2020, March 31, 2020, March 31, 2019, and March 31, 2018, were Rs. 96.74 Million, Rs. 162.13 Million, Rs. 638.22 Million, and Rs. 111.98 Million respectively.
Calculate your return on investment!
Asset Class ROI (Rs.) Profit (Rs.) Profit (%) IPO Equity Savings Real Estate Gold Bonds Fixed Deposit Mutual Fund
|Best Discount Broker in India|
|Top 10 Sub Broker Partner in India|
|Best Stock Broker in India|
|Sub Broker Franchise|
|Best Demat Account|
|Best Full-Service Broker in India|
|Best Intraday Trading Brokers in India|